摘要
目的探讨恩替卡韦对慢性乙型肝炎患者白细胞介素10(IL-10)和转化生长因子β1(TGF-β1)水平的影响及临床意义。方法选取83例慢性乙型肝炎患者,将其按随机原则分为试验组及对照组。试验组42例,口服恩替卡韦0.5 mg,1次/d;对照组41例给予肝泰乐、复合维生素B溶液治疗,疗程均为6个月。治疗前和治疗6个月后,检测血清中IL-10、TGF-β1的含量、肝功能指标及乙型肝炎病毒(HBV)DNA以评价疗效。结果两组治疗后血清中IL-10、TGF-β1水平均显著低于治疗前(P<0.05),试验组[IL-10:(15.42±6.87)ng/L;TGF-β1:(43.96±12.83)ng/L]较对照组[IL-10:(24.56±7.92)ng/L;TGF-β1:(55.63±13.14)ng/L]下降更明显(P<0.05)。治疗后谷丙转氨酶(ALT)、总胆红素(TBIL)和HBV DNA下降,白蛋白(ALB)、凝血酶原活动度(PTA)升高,治疗后ALT和TBIL与对照组比较差异有统计学意义(P<0.05)。结论恩替卡韦可通过降低慢性乙型肝炎患者血清中血清IL-10和TGF-β1水平,提高免疫功能来抑制HBV复制。
Objective To explore the changes and significance of sera levels of IL-10 and TGF-β1 in patients with chronic hepatitis B before and after Entecavir therapy. Methods 83 patients with chronic hepatitis B were randomly assigned to two groups, the treatment group and the control group. Treatment group （42 cases） was treated with Entecavir for 0.5 mg/d, while Glucurone and Compound Vitamin B were given to the control group （41 cases）. The therapeutic course for both groups was 6 months. Before treatment and 6 months after treatment, the level of IL-10 and TGF-β1 were detected. The liver function and serum HBV-DNA were determined. Results After treatment the serum level of IL-10, TGF-β1 decreased than before treatment in the two groups, the difference was significant （P 〈 0.05）, experimental group [IL-10： （15.42±6.87） ng/L; TGF-β1： （43.96±12.83） ng/L] than the control group[IL-10： （24.56±7.92） ng/L; TGF-β1： （55.63±13.14） ng/L] decreased more obviously （P 〈 0.05）; after treatment, ALT, TBIL and HBV DNA declined, ALB and PTA raise, ALT and TBIL compared with control group, the difference was statistically significant （P 〈 0.05）. Conclusion Entecavir may inhibit HBV replication by decreasing the serum IL-10 and TGF-β1 in patients with chronic hepatitis B, which may lead to an enhanced immune function.
出处
《中国医药导报》
CAS
2013年第20期74-76,共3页
China Medical Herald
基金
广西壮族自治区卫生厅自筹经费科研课题(编号Z2008241)
